UA77234C2 - Monohydrate of venlafaxine hydrochloride and methods for its preparation (variants) - Google Patents

Monohydrate of venlafaxine hydrochloride and methods for its preparation (variants) Download PDF

Info

Publication number: UA77234C2
Authority: UA; Ukraine
Prior art keywords: venlafaxine hydrochloride; mammal; effective amount; monohydrate; administering
Prior art date: 2001-12-05

Application number

UA20040705309A

Other languages

English (en)

Ukrainian (uk)

Original Assignee

Wyeth Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-12-05

Filing date

2002-03-12

Publication date

2006-11-15

2002-03-12 Application filed by Wyeth Corp filed Critical Wyeth Corp

2006-11-15 Publication of UA77234C2 publication Critical patent/UA77234C2/uk

Links

229960002416 venlafaxine hydrochloride Drugs 0.000 title claims abstract description 98
QYRYFNHXARDNFZ-UHFFFAOYSA-N venlafaxine hydrochloride Chemical compound [H+].[Cl-].C1=CC(OC)=CC=C1C(CN(C)C)C1(O)CCCCC1 QYRYFNHXARDNFZ-UHFFFAOYSA-N 0.000 title claims abstract description 98
238000000034 method Methods 0.000 title claims abstract description 33
150000004682 monohydrates Chemical class 0.000 title abstract description 17
238000002360 preparation method Methods 0.000 title abstract description 6
239000008194 pharmaceutical composition Substances 0.000 claims description 32
241000124008 Mammalia Species 0.000 claims description 31
230000004048 modification Effects 0.000 claims description 28
238000012986 modification Methods 0.000 claims description 28
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 22
239000000843 powder Substances 0.000 claims description 20
238000002441 X-ray diffraction Methods 0.000 claims description 18
239000000203 mixture Substances 0.000 claims description 17
239000003085 diluting agent Substances 0.000 claims description 5
239000003937 drug carrier Substances 0.000 claims description 5
239000003960 organic solvent Substances 0.000 claims description 5
208000011688 Generalised anxiety disease Diseases 0.000 claims description 4
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
208000029364 generalized anxiety disease Diseases 0.000 claims description 4
208000028173 post-traumatic stress disease Diseases 0.000 claims description 4
238000001953 recrystallisation Methods 0.000 claims description 4
238000005550 wet granulation Methods 0.000 claims description 4
208000019901 Anxiety disease Diseases 0.000 claims description 3
230000001430 anti-depressive effect Effects 0.000 claims description 3
239000000935 antidepressant agent Substances 0.000 claims description 3
229940005513 antidepressants Drugs 0.000 claims description 3
230000036506 anxiety Effects 0.000 claims description 3
208000019906 panic disease Diseases 0.000 claims description 3
230000011273 social behavior Effects 0.000 claims description 2
206010041250 Social phobia Diseases 0.000 claims 1
229960004688 venlafaxine Drugs 0.000 description 17
PNVNVHUZROJLTJ-UHFFFAOYSA-N venlafaxine Chemical compound C1=CC(OC)=CC=C1C(CN(C)C)C1(O)CCCCC1 PNVNVHUZROJLTJ-UHFFFAOYSA-N 0.000 description 15
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 12
238000004090 dissolution Methods 0.000 description 8
238000002844 melting Methods 0.000 description 7
230000008018 melting Effects 0.000 description 7
229910052757 nitrogen Inorganic materials 0.000 description 6
239000003826 tablet Substances 0.000 description 6
238000002411 thermogravimetry Methods 0.000 description 6
241001465754 Metazoa Species 0.000 description 5
239000013078 crystal Substances 0.000 description 5
238000010521 absorption reaction Methods 0.000 description 4
238000004458 analytical method Methods 0.000 description 4
230000018044 dehydration Effects 0.000 description 4
238000006297 dehydration reaction Methods 0.000 description 4
238000006703 hydration reaction Methods 0.000 description 4
239000000546 pharmaceutical excipient Substances 0.000 description 4
239000000126 substance Substances 0.000 description 4
208000020401 Depressive disease Diseases 0.000 description 3
241000282412 Homo Species 0.000 description 3
150000001875 compounds Chemical class 0.000 description 3
230000000994 depressogenic effect Effects 0.000 description 3
208000035475 disorder Diseases 0.000 description 3
230000000694 effects Effects 0.000 description 3
230000036571 hydration Effects 0.000 description 3
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 3
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 3
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 3
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 3
208000013403 hyperactivity Diseases 0.000 description 3
230000002265 prevention Effects 0.000 description 3
230000008569 process Effects 0.000 description 3
238000010926 purge Methods 0.000 description 3
239000007790 solid phase Substances 0.000 description 3
238000002336 sorption--desorption measurement Methods 0.000 description 3
208000011580 syndromic disease Diseases 0.000 description 3
230000007704 transition Effects 0.000 description 3
201000000736 Amenorrhea Diseases 0.000 description 2
206010001928 Amenorrhoea Diseases 0.000 description 2
206010006550 Bulimia nervosa Diseases 0.000 description 2
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical group CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
239000001856 Ethyl cellulose Substances 0.000 description 2
ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 2
201000004311 Gilles de la Tourette syndrome Diseases 0.000 description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical group Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 2
208000008589 Obesity Diseases 0.000 description 2
208000002193 Pain Diseases 0.000 description 2
206010036618 Premenstrual syndrome Diseases 0.000 description 2
GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
208000000323 Tourette Syndrome Diseases 0.000 description 2
208000016620 Tourette disease Diseases 0.000 description 2
206010046543 Urinary incontinence Diseases 0.000 description 2
231100000540 amenorrhea Toxicity 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
238000007664 blowing Methods 0.000 description 2
-1 brighteners Substances 0.000 description 2
239000002775 capsule Substances 0.000 description 2
208000010877 cognitive disease Diseases 0.000 description 2
230000037410 cognitive enhancement Effects 0.000 description 2
239000003405 delayed action preparation Substances 0.000 description 2
238000000113 differential scanning calorimetry Methods 0.000 description 2
239000002552 dosage form Substances 0.000 description 2
229940079593 drug Drugs 0.000 description 2
239000003814 drug Substances 0.000 description 2
235000019325 ethyl cellulose Nutrition 0.000 description 2
229920001249 ethyl cellulose Polymers 0.000 description 2
230000006870 function Effects 0.000 description 2
230000002267 hypothalamic effect Effects 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
239000000463 material Substances 0.000 description 2
230000007246 mechanism Effects 0.000 description 2
230000001272 neurogenic effect Effects 0.000 description 2
235000020824 obesity Nutrition 0.000 description 2
239000012071 phase Substances 0.000 description 2
238000000634 powder X-ray diffraction Methods 0.000 description 2
QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
239000007787 solid Substances 0.000 description 2
238000001179 sorption measurement Methods 0.000 description 2
239000007858 starting material Substances 0.000 description 2
239000000725 suspension Substances 0.000 description 2
239000003029 tricyclic antidepressant agent Substances 0.000 description 2
SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
108060003345 Adrenergic Receptor Proteins 0.000 description 1
102000017910 Adrenergic receptor Human genes 0.000 description 1
206010067484 Adverse reaction Diseases 0.000 description 1
208000008811 Agoraphobia Diseases 0.000 description 1
208000007848 Alcoholism Diseases 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 description 1
206010003805 Autism Diseases 0.000 description 1
208000020706 Autistic disease Diseases 0.000 description 1
208000008035 Back Pain Diseases 0.000 description 1
208000020925 Bipolar disease Diseases 0.000 description 1
208000032841 Bulimia Diseases 0.000 description 1
206010008874 Chronic Fatigue Syndrome Diseases 0.000 description 1
208000022497 Cocaine-Related disease Diseases 0.000 description 1
208000028698 Cognitive impairment Diseases 0.000 description 1
208000032131 Diabetic Neuropathies Diseases 0.000 description 1
241000402754 Erythranthe moschata Species 0.000 description 1
208000001640 Fibromyalgia Diseases 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
229920000168 Microcrystalline cellulose Polymers 0.000 description 1
208000019695 Migraine disease Diseases 0.000 description 1
102000010909 Monoamine Oxidase Human genes 0.000 description 1
108010062431 Monoamine oxidase Proteins 0.000 description 1
241000208125 Nicotiana Species 0.000 description 1
235000002637 Nicotiana tabacum Nutrition 0.000 description 1
208000021384 Obsessive-Compulsive disease Diseases 0.000 description 1
206010034719 Personality change Diseases 0.000 description 1
208000004983 Phantom Limb Diseases 0.000 description 1
206010056238 Phantom pain Diseases 0.000 description 1
208000027030 Premenstrual dysphoric disease Diseases 0.000 description 1
208000003782 Raynaud disease Diseases 0.000 description 1
208000012322 Raynaud phenomenon Diseases 0.000 description 1
201000001880 Sexual dysfunction Diseases 0.000 description 1
206010000059 abdominal discomfort Diseases 0.000 description 1
230000006838 adverse reaction Effects 0.000 description 1
230000000172 allergic effect Effects 0.000 description 1
208000022531 anorexia Diseases 0.000 description 1
230000001078 anti-cholinergic effect Effects 0.000 description 1
239000012298 atmosphere Substances 0.000 description 1
208000010668 atopic eczema Diseases 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
238000009835 boiling Methods 0.000 description 1
239000006172 buffering agent Substances 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
235000010980 cellulose Nutrition 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
230000008859 change Effects 0.000 description 1
201000006145 cocaine dependence Diseases 0.000 description 1
230000006999 cognitive decline Effects 0.000 description 1
239000013256 coordination polymer Substances 0.000 description 1
HPXRVTGHNJAIIH-UHFFFAOYSA-N cyclohexanol Chemical compound OC1CCCCC1 HPXRVTGHNJAIIH-UHFFFAOYSA-N 0.000 description 1
206010061428 decreased appetite Diseases 0.000 description 1
230000006735 deficit Effects 0.000 description 1
208000002173 dizziness Diseases 0.000 description 1
206010013663 drug dependence Diseases 0.000 description 1
230000001544 dysphoric effect Effects 0.000 description 1
208000024732 dysthymic disease Diseases 0.000 description 1
230000002526 effect on cardiovascular system Effects 0.000 description 1
238000001704 evaporation Methods 0.000 description 1
230000008020 evaporation Effects 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
239000000945 filler Substances 0.000 description 1
239000007888 film coating Substances 0.000 description 1
238000009501 film coating Methods 0.000 description 1
238000001914 filtration Methods 0.000 description 1
239000012467 final product Substances 0.000 description 1
238000011010 flushing procedure Methods 0.000 description 1
235000003599 food sweetener Nutrition 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
239000011521 glass Substances 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
230000000742 histaminergic effect Effects 0.000 description 1
239000003906 humectant Substances 0.000 description 1
DKAGJZJALZXOOV-UHFFFAOYSA-N hydrate;hydrochloride Chemical compound O.Cl DKAGJZJALZXOOV-UHFFFAOYSA-N 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
235000013980 iron oxide Nutrition 0.000 description 1
239000008101 lactose Substances 0.000 description 1
239000007788 liquid Substances 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
230000029849 luteinization Effects 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
208000024714 major depressive disease Diseases 0.000 description 1
238000005259 measurement Methods 0.000 description 1
230000010534 mechanism of action Effects 0.000 description 1
FBBDOOHMGLLEGJ-UHFFFAOYSA-N methane;hydrochloride Chemical compound C.Cl FBBDOOHMGLLEGJ-UHFFFAOYSA-N 0.000 description 1
235000019813 microcrystalline cellulose Nutrition 0.000 description 1
239000008108 microcrystalline cellulose Substances 0.000 description 1
229940016286 microcrystalline cellulose Drugs 0.000 description 1
206010027599 migraine Diseases 0.000 description 1
230000003551 muscarinic effect Effects 0.000 description 1
208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 description 1
208000004296 neuralgia Diseases 0.000 description 1
208000021722 neuropathic pain Diseases 0.000 description 1
201000001119 neuropathy Diseases 0.000 description 1
230000007823 neuropathy Effects 0.000 description 1
239000002858 neurotransmitter agent Substances 0.000 description 1
239000003901 neurotransmitter uptake inhibitor Substances 0.000 description 1
229960002748 norepinephrine Drugs 0.000 description 1
SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
230000009965 odorless effect Effects 0.000 description 1
239000012188 paraffin wax Substances 0.000 description 1
208000033808 peripheral neuropathy Diseases 0.000 description 1
239000000825 pharmaceutical preparation Substances 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
239000006187 pill Substances 0.000 description 1
206010036596 premature ejaculation Diseases 0.000 description 1
238000003825 pressing Methods 0.000 description 1
238000012545 processing Methods 0.000 description 1
239000000047 product Substances 0.000 description 1
238000002601 radiography Methods 0.000 description 1
102000005962 receptors Human genes 0.000 description 1
108020003175 receptors Proteins 0.000 description 1
230000001850 reproductive effect Effects 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
201000000980 schizophrenia Diseases 0.000 description 1
239000000932 sedative agent Substances 0.000 description 1
230000001624 sedative effect Effects 0.000 description 1
229940076279 serotonin Drugs 0.000 description 1
231100000872 sexual dysfunction Toxicity 0.000 description 1
230000000391 smoking effect Effects 0.000 description 1
229940079832 sodium starch glycolate Drugs 0.000 description 1
229920003109 sodium starch glycolate Polymers 0.000 description 1
239000008109 sodium starch glycolate Substances 0.000 description 1
239000002904 solvent Substances 0.000 description 1
229910001220 stainless steel Inorganic materials 0.000 description 1
239000010935 stainless steel Substances 0.000 description 1
238000003860 storage Methods 0.000 description 1
238000013268 sustained release Methods 0.000 description 1
239000012730 sustained-release form Substances 0.000 description 1
239000003765 sweetening agent Substances 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
238000012360 testing method Methods 0.000 description 1
239000004408 titanium dioxide Substances 0.000 description 1
235000010215 titanium dioxide Nutrition 0.000 description 1
208000002271 trichotillomania Diseases 0.000 description 1
230000001457 vasomotor Effects 0.000 description 1
230000035899 viability Effects 0.000 description 1
238000005303 weighing Methods 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
- C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
- C07C217/74—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with rings other than six-membered aromatic rings being part of the carbon skeleton
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Biomedical Technology (AREA)
General Chemical & Material Sciences (AREA)
Neurology (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Neurosurgery (AREA)
Emergency Medicine (AREA)
Epidemiology (AREA)
Psychiatry (AREA)
Pain & Pain Management (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

UA20040705309A 2001-12-05 2002-03-12 Monohydrate of venlafaxine hydrochloride and methods for its preparation (variants) UA77234C2 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US33582301P	2001-12-05	2001-12-05
PCT/US2002/038581 WO2003050076A1 (en)	2001-12-05	2002-12-03	Venlafaxine hydrochloride monohydrate and methods for the preparation thereof

Publications (1)

Publication Number	Publication Date
UA77234C2 true UA77234C2 (en)	2006-11-15

Family

ID=23313363

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
UA20040705309A UA77234C2 (en)	2001-12-05	2002-03-12	Monohydrate of venlafaxine hydrochloride and methods for its preparation (variants)

Country Status (20)

Country	Link
US (2)	US20030114536A1 (pl)
EP (1)	EP1451146A1 (pl)
JP (1)	JP2005511737A (pl)
KR (1)	KR20050044711A (pl)
CN (1)	CN1599715A (pl)
AR (1)	AR037636A1 (pl)
AU (1)	AU2002366574A1 (pl)
BR (1)	BR0214696A (pl)
CA (1)	CA2467614A1 (pl)
CO (1)	CO5580817A2 (pl)
EC (1)	ECSP045134A (pl)
HU (1)	HUP0402553A2 (pl)
MX (1)	MXPA04005307A (pl)
NO (1)	NO20042810L (pl)
PL (1)	PL370559A1 (pl)
RU (1)	RU2004120273A (pl)
TW (1)	TW200300669A (pl)
UA (1)	UA77234C2 (pl)
WO (1)	WO2003050076A1 (pl)
ZA (1)	ZA200405245B (pl)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
MXPA04005305A (es) *	2001-12-05	2004-09-13	Wyeth Corp	Nuevo polimorfo cristalino de clorhidrato de venlafaxina y metodos para preparacion del mismo.
KR20070034129A (ko) *	2004-07-22	2007-03-27	와이어쓰	신경계 질환 및 장애의 치료 방법
EP1773321A2 (en) *	2004-07-22	2007-04-18	Wyeth	Method for treating nervous system disorders and conditions
RU2007102292A (ru) *	2004-07-22	2008-08-27	Вайет (Us)	Способ лечения расстройств и заболеваний нервной системы
WO2007047972A2 (en) *	2005-10-19	2007-04-26	Teva Pharmaceutical Industries Ltd.	Process for the preparation of highly pure 1-[2-dimethylamino-(4-methoxyphenyl) ethyl]cyclohexanol hydrochloride
EP2436381A1 (en)	2006-06-27	2012-04-04	Sandoz AG	Crystallization of hydrohalides of pharmaceutical compounds
DK2792662T3 (da)	2007-05-01	2016-07-25	Concert Pharmaceuticals Inc	Morphinanforbindelser
US20120083487A1 (en) *	2008-10-30	2012-04-05	Amanda Thomas	Combination of morphinan compounds and antidepressant for the treatment of pseudobulbar affect, neurolgical diseases, intractable and chronic pain and brain injury
WO2017040611A1 (en) *	2015-08-31	2017-03-09	Nutramax Laboratories, Inc.	Compositions comprising magnolia, phellodendron, theanine and/or whey protein

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DK0639374T3 (da) *	1993-06-28	2002-05-06	American Home Prod	Nye behandlingsmetoder ved anvendelse af phenethylderivater
TW344661B (en) *	1993-11-24	1998-11-11	Lilly Co Eli	Pharmaceutical composition for treatment of incontinence
US5530013A (en) *	1994-02-14	1996-06-25	American Home Products Corporation	Venlafaxine in the inducement of cognition enhancement
US5506270A (en) *	1995-01-30	1996-04-09	American Home Products Corporation	Venlafaxine in the treatment of hypothalamic amenorrhea in non-depressed women
US6274171B1 (en) *	1996-03-25	2001-08-14	American Home Products Corporation	Extended release formulation of venlafaxine hydrochloride
AU2002241764A1 (en) *	2000-10-19	2002-06-18	Teva Pharmaceutical Industries Ltd.	Crystalline venlafaxine base and novel polymorphs of venlafaxine hydrochloride, processes for preparing thereof
US20020183553A1 (en) *	2000-10-19	2002-12-05	Ben-Zion Dolitzky	Crystalline venlafaxine base and novel polymorphs of venlafaxine hydrochloride, processes for preparing thereof
CA2426393C (en) *	2000-10-31	2012-05-29	Ciba Specialty Chemicals Holding Inc.	Crystalline forms of venlafaxine hydrochloride
WO2002046140A1 (en) *	2000-12-07	2002-06-13	Dr. Reddy's Laboratories Ltd.	Novel crystalline polymorphic forms of venlafaxine hydrochloride and a process for their preparation

2002
- 2002-03-12 UA UA20040705309A patent/UA77234C2/uk unknown
- 2002-12-03 CA CA002467614A patent/CA2467614A1/en not_active Abandoned
- 2002-12-03 KR KR1020047008653A patent/KR20050044711A/ko not_active Withdrawn
- 2002-12-03 AU AU2002366574A patent/AU2002366574A1/en not_active Abandoned
- 2002-12-03 MX MXPA04005307A patent/MXPA04005307A/es unknown
- 2002-12-03 EP EP02791360A patent/EP1451146A1/en not_active Withdrawn
- 2002-12-03 BR BR0214696-7A patent/BR0214696A/pt not_active IP Right Cessation
- 2002-12-03 RU RU2004120273/04A patent/RU2004120273A/ru not_active Application Discontinuation
- 2002-12-03 CN CNA028242394A patent/CN1599715A/zh active Pending
- 2002-12-03 JP JP2003551103A patent/JP2005511737A/ja not_active Withdrawn
- 2002-12-03 WO PCT/US2002/038581 patent/WO2003050076A1/en not_active Ceased
- 2002-12-03 US US10/308,472 patent/US20030114536A1/en not_active Abandoned
- 2002-12-03 PL PL02370559A patent/PL370559A1/pl not_active Application Discontinuation
- 2002-12-03 HU HU0402553A patent/HUP0402553A2/hu unknown
- 2002-12-03 TW TW091135029A patent/TW200300669A/zh unknown
- 2002-12-04 AR ARP020104687A patent/AR037636A1/es not_active Application Discontinuation
2004
- 2004-06-01 CO CO04050940A patent/CO5580817A2/es not_active Application Discontinuation
- 2004-06-04 EC EC2004005134A patent/ECSP045134A/es unknown
- 2004-07-01 ZA ZA200405245A patent/ZA200405245B/xx unknown
- 2004-07-02 NO NO20042810A patent/NO20042810L/no not_active Application Discontinuation
2005
- 2005-08-05 US US11/198,041 patent/US20050272822A1/en not_active Abandoned

Also Published As

Publication number	Publication date
TW200300669A (en)	2003-06-16
JP2005511737A (ja)	2005-04-28
AR037636A1 (es)	2004-11-17
NO20042810L (no)	2004-07-02
HUP0402553A2 (hu)	2005-03-29
CN1599715A (zh)	2005-03-23
KR20050044711A (ko)	2005-05-12
ECSP045134A (es)	2004-07-23
MXPA04005307A (es)	2004-09-13
BR0214696A (pt)	2004-11-03
PL370559A1 (pl)	2005-05-30
AU2002366574A1 (en)	2003-06-23
RU2004120273A (ru)	2005-03-27
US20050272822A1 (en)	2005-12-08
CO5580817A2 (es)	2005-11-30
CA2467614A1 (en)	2003-06-19
ZA200405245B (en)	2007-01-31
EP1451146A1 (en)	2004-09-01
US20030114536A1 (en)	2003-06-19
WO2003050076A1 (en)	2003-06-19

Publication	Publication Date	Title
US20100010098A1 (en)	2010-01-14	Polymorphs of rasagiline hydrochloride
US20090005457A1 (en)	2009-01-01	Solid forms comprising (-)-O-desmethylvenlafaxine and uses thereof
US20090291953A1 (en)	2009-11-26	Pharmaceutical salts of reboxetine
US7030164B2 (en)	2006-04-18	Crystalline polymorph of venlafaxine hydrochloride and methods for the preparation thereof
US20030114536A1 (en)	2003-06-19	Venlafaxine hydrochloride monohydrate and methods for the preparation thereof
KR101404836B1 (ko)	2014-06-09	아고멜라틴의 공결정 및 그의 제조방법
EA030553B1 (ru)	2018-08-31	Тапентадола малеат и его кристаллические формы
HK1120035A (en)	2009-03-20	Pharmaceutical salts of reboxetine
HK1071884A (en)	2005-08-05	Venlafaxine hydrochloride monohydrate and methods for the preparation thereof
HK1077572B (en)	2010-09-03	Pharmaceutical salts of reboxetine